Are the available low-molecular-weight heparin preparations the same?

Area of Science:

• Pharmacology
• Biochemistry
• Thrombosis research

Background:

• Low molecular weight heparins (LMWHs) are standard for post-surgical deep vein thrombosis (DVT) prophylaxis and are explored for other indications.
• Manufacturing variations result in distinct pharmacologic and biochemical profiles for each LMWH product.

Purpose of the Study:

• To compare the pharmacologic profiles of different LMWHs.
• To investigate product individuality in antithrombotic and hemorrhagic effects.
• To assess the role of tissue factor pathway inhibitor (TFPI) release.

Main Methods:

• Evaluation of specific activities (anti-IIa and anti-Xa units).
• Assessment of dose- and time-dependent antithrombotic effects in animal models.
• Monitoring of TFPI release after intravenous (i.v.) and subcutaneous (s.c.) administration in primate models.
• Comparison of antithrombotic and hemorrhagic effects with repeated administration.

Main Results:

• LMWHs exhibit product-specific activities and dose-dependent antithrombotic effects.
• Sustained antithrombotic effects can occur without detectable ex vivo anticoagulant activity.
• TFPI release varies by LMWH product and administration route (i.v./s.c.).
• Repeated administration shows product-dependent augmentation of antithrombotic or hemorrhagic effects.

Conclusions:

• Product individuality significantly influences LMWH efficacy and safety.
• Standardization protocols do not adequately guide LMWH substitution or predict clinical outcomes.
• TFPI release is a relevant factor in LMWH action, highlighting product-specific mechanisms.